Lecithin-based cationic nanoparticles as a potential DNA delivery system

被引:31
作者
Cui, ZR [1 ]
Qiu, F [1 ]
Sloat, BR [1 ]
机构
[1] Oregon State Univ, Dept Pharmaceut Sci, Coll Pharm, Corvallis, OR 97331 USA
关键词
cytotoxicity; stability; transfection;
D O I
10.1016/j.ijpharm.2006.01.042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Previously, we have reported a novel nanoparticle-based DNA vaccine delivery system. which elicited strong immune responses against antigens of interest encoded by the DNA. The nanoparticles were engineered by cooling pre-formed warm microemulsions comprised of emulsifying wax as the oil phase and hexadecyl trim ethyl ammonium bromide (CTAB) as the surfactant. However, the poor aqueous stability of the nanoparticles and the emulsifying wax in the nanoparticles may severely limit the applications of the nanoparticles. In the present study, we used lecithin, a more biocompatible, material, instead of emulsifying wax, to prepared lecithin-based cationic nanoparticles. The 50% growth inhibition concentration (IC50) of the lecithin-based nanoparticles was found to be more than 1000-fold higher than that of the emulsifying wax-based nanoparticles. Moreover, the stability of the lecithin nanoparticles was also significantly increased. The size of the nanoparticles did not significantly change during a 6-month storage period at room temperature. Finally, when plasmid DNA was adsorbed on their surface, the lecithin nanoparticles successfully transfected cells in culture. These lecithin-based nanoparticles may hold great potentials as a DNA (vaccine) delivery system. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:206 / 213
页数:8
相关论文
共 25 条
[11]   INTRANASAL ADMINISTRATION OF INSULIN WITH PHOSPHOLIPID AS ABSORPTION ENHANCER - PHARMACOKINETICS IN NORMAL SUBJECTS [J].
DREJER, K ;
VAAG, A ;
BECH, K ;
HANSEN, P ;
SORENSEN, AR ;
MYGIND, N .
DIABETIC MEDICINE, 1992, 9 (04) :335-340
[12]  
GROWDON JH, 1978, NEW ENGL J MED, V298, P1029
[13]   Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase [J].
Hattori, Y ;
Maitani, Y .
CANCER GENE THERAPY, 2005, 12 (10) :796-809
[14]   Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles:: In vitro and in vivo studies [J].
Kaul, G ;
Amiji, M .
PHARMACEUTICAL RESEARCH, 2005, 22 (06) :951-961
[15]   Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles [J].
Kaul, G ;
Amiji, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (01) :184-198
[16]   Physicochemical characterization of poly(L-lactic acid) and poly(D,L-lactide-co-glycolide) nanoparticles with polyethylenimine as gene delivery carrier [J].
Kim, IS ;
Lee, SK ;
Park, YM ;
Lee, YB ;
Shin, SC ;
Lee, KC ;
Oh, IJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 298 (01) :255-262
[17]   Mechanism of efficient transfection of the nasal airway epithelium by hypotonic shock [J].
Lemoine, JL ;
Farley, R ;
Huang, L .
GENE THERAPY, 2005, 12 (16) :1275-1282
[18]   Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation [J].
Locher, CP ;
Putnam, D ;
Langer, R ;
Witt, SA ;
Ashlock, BM ;
Levy, JA .
IMMUNOLOGY LETTERS, 2003, 90 (2-3) :67-70
[19]   Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo [J].
Rudolph, C ;
Schillinger, U ;
Ortiz, A ;
Tabatt, K ;
Plank, C ;
Müller, RH ;
Rosenecker, J .
PHARMACEUTICAL RESEARCH, 2004, 21 (09) :1662-1669
[20]   Structural evolution in cationic micelles upon incorporation of a polar organic dopant [J].
Singh, M ;
Ford, C ;
Agarwal, V ;
Fritz, G ;
Bose, A ;
John, VT ;
McPherson, GL .
LANGMUIR, 2004, 20 (23) :9931-9937